|

Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma

RECRUITINGSponsored by Università degli Studi 'G. d'Annunzio' Chieti e Pescara
Actively Recruiting
SponsorUniversità degli Studi 'G. d'Annunzio' Chieti e Pescara
Started2026-03-24
Est. completion2027-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07777406

Summary

A multicenter, non-interventional, observational, retrospective and prospective pharmacological study aimed at evaluating the use of allogeneic hematopoietic stem cell transplantation in patients with relapsed/refractory multiple myeloma.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* patients diagnosed with relapsed/refractory multiple myeloma according to IMWG criteria who have undergone allogeneic hematopoietic stem cell transplantation;
* Age ≥ 18 years;
* Signature of the informed consent form (where possible).

Exclusion Criteria:

* Patients diagnosed with primary AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), indolent multiple myeloma, or primary plasma cell leukemia;
* Patients who have not undergone allogeneic hematopoietic stem cell transplantation;
* Age \< 18 years.

Conditions2

CancerPlasma Cell Neoplasms

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.